BMRN vs EOLS · P/E 40, rev $2.85B vs rev $266.3M
Biomarin Pharmaceutical Inc (BMRN) versus Evolus Inc (EOLS) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Evolus Inc (EOLS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported EOLS revenue for 2024-12-31 was $266.3M. Net income was -$50.4M. Revenue was up 31.8% from 2023-12-31 to 2024-12-31. EOLS currently screens at market cap $597.0M.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. EOLS currently screens at market cap $597.0M.
Not investment advice. Open the BMRN and EOLS stock pages for the full models.
Not investment advice.